Case Study

Overcoming Limitations To Achieve Uniform Dosing

Source: Cambrex

By Tracy Milburn, Director, Analytical Services, Cambrex

iStock-827580992-lab-research-development

Drug companies often consider the value of CDMOs in terms of process development to meet milestones for regulatory filings and scale-up efforts for commercialization. However, specific needs in the clinic can also drive new efforts in method development and drug product formulation. Choosing the right CDMO with the proper experience and facilities can make or break the ability to deliver swift modifications to a formulation.

Formulations of low-dose drugs require a careful balance of several factors to ensure that each dosage has an acceptable blend and content uniformity. Determining the right methods and equipment specifications to pair with the selected material requires expertise across multiple areas of the development process. In this case, an immediate need for lower dose capsules in the clinic posed several challenges in blend formulation with very tight timelines for delivery. With the equipment already optimized to deliver the smallest dose, Cambrex targeted modifications to the formulation to solve the client’s needs. The analytical team worked on multiple fronts while also supporting the manufacturing team, and delivered qualified methods to support release testing of batches of the new formulation.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: